Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fiorini, Ada ^a   Koudriavtseva, Tatiana ^b   Bucaj, Elona ^b   Coccia, Raffaella ^a   Foppoli, Cesira ^c   Giorgi, Alessandra ^a   Schininà, M Eugenia ^a   Di Domenico, Fabio ^a   de Marco, Federico ^b   Perluigi, Marzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; CERULOPLASMIN; CLUSTERIN; COMPLEMENT COMPONENT C3; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING;

ADULT; APOLIPOPROTEINS A; BLOOD PROTEINS; CASE-CONTROL STUDIES; DEMOGRAPHY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VITAMIN D-BINDING PROTEIN;

EID: 84878752933     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065184     Document Type: Article

References (55)

1. Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 58: 840-846.
2. Compston A, Coles A, (2008) Multiple sclerosis. The Lancet 372: 1502-1517.
3. Silber E, Sharief MK, (1999) Axonal degeneration in the pathogenesis of multiple sclerosis. Journal of the Neurological Sciences 170: 11-18.
4. Trapp BD, Ransohoff R, Rudick R, (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302.
5. Gonsette RE, (2008) Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. Journal of the Neurological Sciences 274: 48-53.
6. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I, (2012) Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clinical Biochemistry 45: 26-30.
7. Ortiz GG, Macías-Islas MÁ, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, et al. (2009) Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Disease Markers 26: 35-39.
8. Stavropoulou C, Zachaki S, Alexoudi A, Chatzi I, Georgakakos VN, et al. (2011) The C609T inborn polymorphism in NAD(P)H:quinone oxidoreductase 1 is associated with susceptibility to multiple sclerosis and affects the risk of development of the primary progressive form of the disease. Free Radical Biology and Medicine 51: 713-718.
9. Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A, (2005) Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. Journal of Neuroscience Research 81: 687-695.
10. Greco A, Minghetti L, Sette G, Fieschi C, Levi G, (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53: 1876.
11. Tasset I, Agüera E, Sánchez-López F, Feijóo M, Giraldo AI, et al. (2012) Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clinical Biochemistry 45: 440-444.
12. Luessi F, Siffrin V, Zipp F, (2012) Neurodegeneration in multiple sclerosis: novel treatment strategies. Expert Review of Neurotherapeutics 12: 1061-1077.
13. Butterfield DA, Perluigi M, Sultana R, (2006) Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. European Journal of Pharmacology 545: 39-50.
14. Dalle-Donne I, Scaloni A, Giustarini D, Cavarra E, Tell G, et al. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: The contribution of redox proteomics. Mass Spectrometry Reviews 24: 55-99.
15. Singh V, Hintzen RQ, Luider TM, Stoop MP, (2012) Proteomics technologies for biomarker discovery in multiple sclerosis. Journal of Neuroimmunology 248: 40-47.
16. Chiasserini D, Di Filippo M, Candeliere A, Susta F, Orvietani PL, et al. (2008) CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. European Journal of Neurology 15: 998-1001.
17. Liu S, Bai S, Qin Z, Yang Y, Cui Y, et al. (2009) Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. Journal of Cellular and Molecular Medicine 13: 1586-1603.
18. Teunissen C, Koel-Simmelink M, Pham T, Knol J, Khalil M, et al. (2011) Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Multiple Sclerosis Journal 17: 838-850.
19. Stoop MP, Singh V, Dekker LJ, Titulaer MK, Stingl C, et al. (2010) Proteomics Comparison of Cerebrospinal Fluid of Relapsing Remitting and Primary Progressive Multiple Sclerosis. PLoS ONE 5: e12442.
20. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology 69: 292-302.
21. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, et al. (1965) Problems Of Experimental Trials Of Therapy In Multiple Sclerosis: Report By The Panel On The Evaluation Of Experimental Trials Of Therapy In Multiple Sclerosis. Annals of the New York Academy of Sciences 122: 552-568.
22. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW, (2005) Investigating diversity in human plasma proteins. Proceedings of the National Academy of Sciences of the United States of America 102: 10852-10857.
23. Alsaif M, Guest PC, Schwarz E, Reif A, Kittel-Schneider S, et al. (2012) Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection. Proteomics Clin Appl 6: 297-303.
24. Perluigi M, Giorgi A, Blarzino C, De Marco F, Foppoli C, et al. (2009) Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. Journal of Cellular and Molecular Medicine 13: 1809-1822.
25. Pappin DJ, (2003) Peptide mass fingerprinting using MALDI-TOF mass spectrometry. Methods Mol Biol 211: 211-219.
26. Berlett BS, Stadtman ER, (1997) Protein Oxidation in Aging, Disease, and Oxidative Stress. Journal of Biological Chemistry 272: 20313-20316.
27. Gilgun-Sherki Y, Melamed E, Offen D, (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. Journal of Neurology 251: 261-268.
28. Oliveira SR, Kallaur AP, Simão ANC, Morimoto HK, Lopes J, et al. (2012) Oxidative stress in multiple sclerosis patients in clinical remission: Association with the expanded disability status scale. Journal of the Neurological Sciences 321: 49-53.
29. Bradl M, Lassmann H, (2009) Progressive multiple sclerosis. Semin Immunopathol 31: 455-465.
30. Trapp BD, Nave KA, (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31: 247-269.
31. Rithidech K, Honikel L, Milazzo M, Madigan D, Troxell R, et al. (2009) Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Multiple Sclerosis 15: 455-464.
32. Trougakos IP, Gonos ES, (2006) Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radical Research 40: 1324-1334.
33. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR, (1999) Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins. Journal of Biological Chemistry 274: 6875-6881.
34. Disanto G, Ramagopalan S, Para A, Handunnetthi L, (2011) The emerging role of vitamin D binding protein in multiple sclerosis. Journal of Neurology 258: 353-358.
35. Roussel BD, Macrez R, Jullienne A, Agin V, Maubert E, et al. (2009) Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 132: 2219-2230.
36. Chapman J, (2006) Thrombin in inflammatory brain diseases. Autoimmunity Reviews 5: 528-531.
37. Cicala C, Cirino G, (1998) Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk. Life Sciences 62: 1817-1824.
38. Esmon CT, (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86: 51-56.
39. Beresford CH, Owen MC, (1990) Antithrombin III. Int J Biochem 22: 121-128.
40. Beilin O, Karussis DM, Korczyn AD, Gurwitz D, Aronovich R, et al. (2005) Increased thrombin inhibition in experimental autoimmune encephalomyelitis. Journal of Neuroscience Research 79: 351-359.
41. Inaba Y, Ichikawa M, Koh C-S, Inoue A, Itoh M, et al. (1999) Suppression of Experimental Autoimmune Encephalomyelitis by Dermatan Sulfate. Cellular Immunology 198: 96-102.
42. Turk R, Piras C, Kovačić M, Samardžija M, Ahmed H, et al. (2012) Proteomics of inflammatory and oxidative stress response in cows with subclinical and clinical mastitis. Journal of Proteomics 75: 4412-4428.
43. Del Boccio P, Pieragostino D, Di Ioia M, Petrucci F, Lugaresi A, et al. (2011) Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. Journal of Proteomics 74: 2826-2836.
44. D'Aguanno S, Barassi A, Lupisella S, d'eril GM, Del Boccio P, et al. (2008) Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. Journal of Neuroimmunology 193: 156-160.
45. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P, (1998) Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. American Journal of Physiology- Heart and Circulatory Physiology 274: H1836-H1840.
46. Olmarker K, Nordborg C, Larsson K, Rydevik B, (1996) Ultrastructural changes in spinal nerve roots induced by autologous nucleus pulposus. Spine (Phila Pa 1976) 21: 411-414.
47. Sun HQ, Yamamoto M, Mejillano M, Yin HL, (1999) Gelsolin, a Multifunctional Actin Regulatory Protein. Journal of Biological Chemistry 274: 33179-33182.
48. Kwiatkowski DJ, Stossel TP, Orkin SH, Colten HR, Yin HL, (1986) Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323: 455-458.
49. Lind SE, Smith dB, Janmey PA, Stossel TP, (1986) Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 78: 736-742.
50. Kulakowska A, Ciccarelli NJ, Wen Q, Mroczko B, Drozdowski W, et al. (2010) Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis. BMC Neurol.
51. Kulakowska A, Drozdowski W, Sadzynski A, Bucki R, Janmey PA, (2008) Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders. European Journal of Neurology 15: 584-588.
52. Koya RC, Fujita H, Shimizu S, Ohtsu M, Takimoto M, et al. (2000) Gelsolin Inhibits Apoptosis by Blocking Mitochondrial Membrane Potential Loss and Cytochrome c Release. Journal of Biological Chemistry 275: 15343-15349.
53. Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, et al. (2009) Cytoplasmic gelsolin increases mitochondrial activity and reduces Aβ burden in a mouse model of Alzheimer's disease. Neurobiology of Disease 36: 42-50.
54. Zipp F, (2000) Apoptosis in multiple sclerosis. Cell Tissue Res 301: 163-171.
55. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, et al. (2003) Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis & Rheumatism 48: 248-254.